Insulin Delivery Systems Market Forecast to 2014 -

 Number of Pages:  90
Date Published:  February 2012

The global medical fraternity is alarmed at the rate at which the diabetic population has been increasing worldwide. It is expected that the number of diabetic patients in the world will reach around 552 Million by 2030. With such startlingly constant growth, the demand for diabetes solutions is increasing exceptionally across the globe and has cascading effects on testing equipment and delivery devices market. According to our latest research report, the insulin delivery system market is currently characterized by the emergence of new drug delivery devices, and this trend is likely to continue in the coming few years.  

Our recent research “Insulin Delivery Systems Market Forecast to 2014”, states that manufacturers and service providers are recognizing and catering to the special needs of diabetics. As per our estimations, the global insulin delivery systems market will grow at a CAGR of around 8% during 2012-2014. The insulin delivery systems include insulin syringes, pens, pumps and jet injectors. According to our study, insulin syringes and pens dominate the global insulin delivery systems market. Besides, market penetration of both insulin pumps and needle-free injection jets is also rising due to technological advances.  

On analyzing the recent trends and studying the latest developments, we found that a number of new insulin delivery systems will enter the market this year (2012), and these launches will open up new avenues of growth in the sector. Implantable insulin pumps, insulin inhalers and Insulin pump patches are among the emerging devices in the insulin delivery system market. The geographic segmentation analysis carried out in the research revealed how and to what extent the insulin delivery system market is growing in countries like India, China, and the US, among others.  

A brief overview of traditional delivery devices and new & emerging technological products has been included in the study to present a balanced outlook of the industry. With a view to understanding the competitive landscape, we also studied and included profiles of key market players in the report. Overall, we have tried to include each and every significant detail relating to the global insulin delivery systems market in our comprehensive research in order to make it understandable to clients who are eyeing opportunities in the segment.  



  • 1. Analyst View 
  • 2. Research Methodology 
  • 3. Global Diabetes Drug Market Overview 
  • 4. Key Market Drivers 
  • 5. Global Insulin Delivery Devices Market Overview 
    • 5.1 India 
      • 5.1.1 Prevalence 
      • 5.1.2 Market Analysis 
    • 5.2 China 
      • 5.2.1 Prevalence 
      • 5.2.2 Market Analysis 
    • 5.3 US 
      • 5.3.1 Prevalence 
      • 5.3.2 Market Analysis 
    • 5.4 Russia 
      • 5.4.1 Prevalence 
      • 5.4.2 Market Analysis 
    • 5.5 Brazil 
      • 5.5.1 Prevalence 
      • 5.5.2 Market Analysis 
  • 6. Insulin Delivery Devices 
    • 6.1 Insulin Pens 
      • 6.1.1 Mechanism and Technologies 
      • 6.1.2 Pros and Cons 
      • 6.1.3 Market Analysis 
      • 6.1.4 Key Players and Products 
    • 6.2 Insulin Pumps 
      • 6.2.1 Mechanism and Technologies 
      • 6.2.2 Pros and Cons 
      • 6.2.3 Market Analysis 
      • 6.2.4 Key Players and Products 
    • 6.3 Insulin Syringes 
      • 6.3.1 Mechanism and Technologies 
      • 6.3.2 Pros and Cons 
      • 6.3.3 Market Analysis 
      • 6.3.4 Key Players and Products 
    • 6.4 Insulin Jet Injectors 
      • 6.4.1 Mechanism and Technologies 
      • 6.4.2 Pros and Cons 
      • 6.4.3 Market Analysis 
      • 6.4.4 Key Players and Products 
  • 7. Emerging Devices 
    • 7.1 Implantable Insulin Pumps 
    • 7.2 Insulin Inhalers 
    • 7.3 Oral Insulin/Insulin Pill 
    • 7.4 Vaccines 
    • 7.5 MEMS Technology 
    • 7.6 Islet Cell Transplantation 
    • 7.7 Insulin Patch 
    • 7.8 Insulin Patch Pump 
  • 8. Key Players 
    • 8.1 Novo Nordisk 
    • 8.2 Eli Lilly 
    • 8.3 Medtronic 
    • 8.4 Becton Dickinson 
    • 8.5 Sanofi Aventis 
    • 8.6 F. Hoffmann La Roche